Actively Recruiting
New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients
Led by University Hospital, Montpellier · Updated on 2022-01-04
250
Participants Needed
7
Research Sites
950 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin, fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a 7 year follow-up.
CONDITIONS
Official Title
New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed the written consent form
- Chronic kidney disease with reduced glomerular filtration rate but not requiring dialysis
You will not qualify if you...
- Pregnant
- Chronic kidney disease requiring dialysis therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
AIDER
Montpellier, France
Actively Recruiting
2
CHU Montpellier, Cardiology department
Montpellier, France
Active, Not Recruiting
3
CHU Montpellier, Endocrinology department
Montpellier, France
Actively Recruiting
4
CHU Montpellier, Intensive care unit
Montpellier, France
Active, Not Recruiting
5
CHU Montpellier, Internal medicine department
Montpellier, France
Active, Not Recruiting
6
CHU Montpellier, Nephrology department
Montpellier, France
Actively Recruiting
7
AIDER
Saint-Jean-de-Védas, France
Not Yet Recruiting
Research Team
J
Jean-Paul CRISTOL, Prof
CONTACT
M
Marion Morena, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here